Renalytix PLC RENX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RENX is a good fit for your portfolio.
News
-
Renalytix Announces Financing with Expected Size of up to $4 Million
-
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
-
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
-
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Renalytix Gets FDA De Novo Marketing Authorization for KidneyIntelX.dkd
Trading Information
- Previous Close Price
- GBX 25.50
- Day Range
- GBX 24.00–25.20
- 52-Week Range
- GBX 10.00–150.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 3.13 Bil
- Volume/Avg
- 170,170 / 759,463
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.19
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
- Sector
- Healthcare
- Industry
- Health Information Services
- Stock Style Box
- Small Value
- Total Number of Employees
- 110
- Website
- https://www.renalytix.com
Comparables
Valuation
|
Metric
|
RENX
|
ZURA
|
GHRS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 2.66 | 2.50 |
Price/Sales | 12.19 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
RENX
ZURA
GHRS
Financial Strength
|
Metric
|
RENX
|
ZURA
|
GHRS
|
|---|---|---|---|
Quick Ratio | 0.59 | 4.92 | 24.14 |
Current Ratio | 0.68 | 4.97 | 24.49 |
Interest Coverage | — | — | −706.38 |
Quick Ratio
RENX
ZURA
GHRS
Profitability
|
Metric
|
RENX
|
ZURA
|
GHRS
|
|---|---|---|---|
Return on Assets (Normalized) | −136.50% | −71.08% | −12.75% |
Return on Equity (Normalized) | −918.80% | −139.85% | −13.12% |
Return on Invested Capital (Normalized) | −217.18% | −99.89% | −16.87% |
Return on Assets
RENX
ZURA
GHRS
Health Information Services Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
GEHC
| GE HealthCare Technologies Inc Common Stock | — | Ktjxgm | $39.4 Bil | |
VEEV
| Veeva Systems Inc Class A | Lrsxjchpw | Skz | $32.4 Bil | |
SOLV
| Solventum Corp | — | Jzcsw | $11.1 Bil | |
MTHRF
| M3 Inc | — | Yddjt | $8.2 Bil | |
MTHRY
| M3 Inc ADR | — | Wtsjtn | $8.2 Bil | |
PMCUF
| Pro Medicus Ltd | — | Zhnymkx | $7.5 Bil | |
HQY
| HealthEquity Inc | — | Hwvrtxr | $6.8 Bil | |
RCM
| R1 RCM Inc | — | Zvfk | $5.0 Bil | |
DOCS
| Doximity Inc Class A | — | Gkwhx | $4.4 Bil | |
EVH
| Evolent Health Inc Class A | — | Wprjv | $3.3 Bil |